Top Markets
Coin of the day
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc

FRLN
Rank in Stocks #30823
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in... Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.
Share Price
$6.48
Last synced: 2024-02-29
Market Cap
$15.41M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
GB
Trade Freeline Therapeutics Holdings plc (FRLN)

Category

Stock price history for Freeline Therapeutics Holdings plc (FRLN)
Highest end of day price: $6.46 on 2024-02-01

Lowest end of day price: $253.54 on 2020-08-01
Stock price history of Freeline Therapeutics Holdings plc from 2020 to 2026
Annual Stock Price Performance
Year Performance
2024 1.37%
2023 -20.74%
2022 -75.54%
2021 -87.40%
2020 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$527.89 35.40%
US
$996.61 50.70%
NL
$111.31 -36.83%
AU
$735.86 6.87%
CH
$257.75 13.01%
BE